RaiNews24, the national TV channel reporting on Italian news, interviews Gessica Filocamo, Exiris Director of Biology Labs, on their pharmaceutical research, as part of the research community of biotech companies... read more →

Exiris Human Antibody Phage Display Library for identification of high affinity monoclonal antibodies, without need of further affinity maturation, will be presented at the FOB 2019 https://www.terrapinn.com/conference/festival-of-biologics/index.stm. Details on several... read more →

Exiris is part of the European Training Network (ETN) MAGICBULLET, which was launched by the European Union in 2015 as part of the HORIZON 2020 program for research and innovation... read more →

Data are presented on novel cryptophycin-based peptide conjugates for tumor targeting, generated in the context of the Horizon 2020 MAGICBULLET project.

Exiris presents data on novel cytotoxic peptide-drug conjugates for tumor targeted therapy, generated in collaboration with the University of Bielefeld and Italfarmaco within the Horizon 2020 MAGICBULLET project. Two lectures... read more →

Project funded by   Project: Therapeutic Antibody Service Technologies Description of the project. The TASTE project aims to develop technological services based on... read more →

Exiris, in collaboration with the Italian Institute of Health (ISS), Rome and with Aldevron Freiburg Germany, has generated a novel antibody that shows efficacy against colon cancer stem cell and... read more →

Data are presented on novel cryptophycin-based antibody- and peptide-drug conjugates for tumor targeted therapy, generated in collaboration with the University of Bielefeld

Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron on the development of novel anticancer agents. According to two separate agreements, Exiris acquires exclusive rights to,... read more →